<DOC>
	<DOCNO>NCT02237729</DOCNO>
	<brief_summary>This Phase 1 , double blind ( sponsor open ) , randomize ( 1:1:1 ) , parallel group , 3 arm , single dose comparative PK study adalimumab Pfizer adalimumab source US EU administer subcutaneously ( SC ) healthy male female volunteer</brief_summary>
	<brief_title>A Study Of PF-06410293 ( Adalimumab-Pfizer ) And Adalimumab ( Humira ) In Healthy Subjects ( REFLECTIONS B538-07 ) )</brief_title>
	<detailed_description />
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Healthy male female subject age 18 45 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , complete physical examination include blood pressure heart rate measurement , 12 lead ECG clinical laboratory test . Body Mass Index ( BMI ) 19.0 30.5 kg/m2 ; total body weight &gt; 60 kg ( 132 lb ) . Chest X ray evidence current , active TB previous ( inactive ) TB , general infection , heart failure , malignancy , clinically significant abnormality take Screening within 24 week prior Day 1 read qualify radiologist . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , autoimmune , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Previous history cancer , except adequately treat basal cell squamous cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>healthy subject</keyword>
	<keyword>immunology</keyword>
	<keyword>PK</keyword>
	<keyword>Phase 1</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>biosimilarity</keyword>
	<keyword>adalimumab</keyword>
	<keyword>single dose .</keyword>
</DOC>